When did GRITSTONE BIO INC (GRTS) report earnings last quarter?
GRITSTONE BIO INC (GRTS) last reported earnings on 8/13/2024.
GRITSTONE BIO INC (GRTS) Earnings History & Surprises
NASDAQ:GRTS • US39868T1051
Current stock price
0.0322 USD
-0.01 (-31.78%)
At close:
0.026 USD
-0.01 (-19.25%)
After Hours:
GRTS Earnings overview
Past quarterly earnings results for GRITSTONE BIO INC (GRTS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Nov 7, 2024
- Period
- Q3 / 2024
- EPS Estimate
- -$0.19
- Revenue Estimate
Last Reported
Most Recent- Release Date
- Aug 13, 2024
- Period
- Q2 / 2024
- EPS Reported
- -$0.16
- EPS Surprise
- 44.55%
- Revenue Surprise
- -34.21%
Beat Rate
Last 8 Quarters 63%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2024 | -0.16 | -0.29 | 44.55% | 48.39% | 921K | 1.4M | -34.21% | -52.89% |
| Q1 2024 | -0.34 | -0.32 | -4.70% | -13.33% | 1.742M | 1.126M | 54.71% | -28.69% |
| Q4 2023 | -0.26 | -0.33 | 22.26% | 13.33% | 10.383M | 5.215M | 99.10% | 143.73% |
| Q3 2023 | -0.33 | -0.34 | 2.80% | 5.71% | 1.565M | 1.932M | -19.00% | -48.18% |
| Q2 2023 | -0.31 | -0.35 | 12.29% | 8.82% | 1.955M | 2.55M | -23.33% | -64.26% |
| Q1 2023 | -0.30 | -0.34 | 12.07% | 11.76% | 2.443M | 3.23M | -24.37% | -66.02% |
| Q4 2022 | -0.30 | -0.35 | 14.50% | 18.92% | 4.26M | 2.961M | 43.87% | 39.22% |
| Q3 2022 | -0.35 | -0.41 | 13.78% | 2.78% | 3.02M | 3.68M | -17.93% | 15.71% |
| Q2 2022 | -0.34 | -0.40 | 15.82% | -3.03% | 5.47M | 3.256M | 68.00% | 92.61% |
| Q1 2022 | -0.34 | -0.37 | 9.30% | -440.00% | 7.19M | 4.297M | 67.33% | -81.88% |
| Q4 2021 | -0.37 | -0.39 | 5.16% | 46.38% | 3.06M | 2.92M | 4.79% | 126.67% |
| Q3 2021 | -0.36 | -0.53 | 32.00% | 47.83% | 2.61M | 2.282M | 14.37% | 177.66% |
| Q2 2021 | -0.33 | -0.59 | 43.95% | 52.17% | 2.84M | 2.282M | 24.45% | 479.59% |
| Q1 2021 | 0.10 | -0.40 | 125.07% | 114.08% | 39.69M | 12.457M | 218.62% | 3,050.00% |
| Q4 2020 | -0.69 | -0.62 | -10.44% | - | 1.35M | 1.237M | 9.14% | - |
| Q3 2020 | -0.69 | -0.65 | -5.37% | - | 940K | 1.081M | -13.04% | - |
| Q2 2020 | -0.69 | -0.74 | 7.15% | - | 490K | 1.254M | -60.93% | - |
| Q1 2020 | -0.71 | -0.74 | 4.60% | - | 1.26M | 1.333M | -5.48% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
16.23%
Max EPS beat (4)
44.55%
Min EPS beat (4)
-4.70%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
25.15%
Max Revenue beat (4)
99.10%
Min Revenue beat (4)
-34.21%
Analysis
In the last 4 quarters, GRTS has beaten EPS estimates in 3 out of 4 releases
GRTS has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, GRTS has beaten the EPS estimates by 16.2% on average.
In the last 4 quarters, GRTS has beaten the revenue estimates by 25.1% on average.
Related analysis
GRITSTONE BIO INC / GRTS Earnings FAQ
Did GRITSTONE BIO INC (GRTS) beat earnings estimates last quarter?
GRITSTONE BIO INC (GRTS) beat EPS estimates and missed revenue estimates in the most recent quarter.
How often does GRITSTONE BIO INC (GRTS) beat earnings estimates?
In the last 4 quarters, GRITSTONE BIO INC (GRTS) has beaten EPS estimates in 3 out of 4 releases.